# Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer
Canonical URL: https://biopharmsignal.com/news/SEER/seer-announces-appointment-of-anthony-bazarko-as-chief-commercial-officer
Ticker: SEER
Company: Seer, Inc
Source: Seer, Inc
Published: 2026-05-04 11:00 EST
Original Source URL: https://investor.seer.bio
## Summary

Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer’s Proteograph ® Product Suite REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic

## Article Body
Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer’s Proteograph ® Product Suite REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic
## Recent Company News
- 2026-06-03 22:00 EST — [Seer Files Definitive Proxy Materials and Mails Letter to Stockholders](https://biopharmsignal.com/news/SEER/seer-files-definitive-proxy-materials-and-mails-letter-to-stockholders) — Source: Seer, Inc
- 2026-05-29 11:00 EST — [Seer Files ITC Complaint Against Nanomics](https://biopharmsignal.com/news/SEER/seer-files-itc-complaint-against-nanomics) — Source: Seer, Inc
- 2026-05-26 20:05 EST — [Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026](https://biopharmsignal.com/news/SEER/seer-to-showcase-ai-driven-multi-cancer-screening-approach-and-next-generation-proteomics-capabilities-at-asms-2026) — Source: Seer, Inc
- 2026-05-21 20:39 EST — [Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group](https://biopharmsignal.com/news/SEER/seer-board-of-directors-unanimously-rejects-further-revised-unsolicited-proposal-from-radoff-jec-group) — Source: Seer, Inc
- 2026-05-13 20:05 EST — [Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook](https://biopharmsignal.com/news/SEER/seer-reports-first-quarter-2026-financial-results-and-reaffirms-full-year-2026-outlook) — Source: Seer, Inc
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)